MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in...

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Many tumors lose MHC class I expression during development from MHC class I+ precursors.
• Developing polyvalent tumor vaccines is crucial for effective cancer immunotherapy against diverse malignancies.

Purpose of the Study:

• To investigate cross-protection between MHC class I-positive (MHC class I+) and MHC class I-negative (MHC class I-) tumor vaccines.
• To assess if vaccines targeting shared tumor antigens can elicit cross-protective immunity.

Main Methods:

• Utilized two independently induced oncogenic cell lines (TC-1 and MK16/1/IIIABC) in syngeneic mice.
• TC-1 tumors express HPV16 E7 antigen and are MHC class I+; MK16/1/IIIABC tumors are MHC class I-.
• Evaluated cross-protection by pre-immunizing mice with one tumor type and challenging with the other.

Main Results:

• No cross-protection was observed between MHC class I+ and MHC class I- tumors, despite both expressing the HPV16 E7 antigen.
• Pre-immunization with MHC class I+ tumors did not protect against MHC class I- tumor challenge, and vice versa.
• Autologous immunization (e.g., TC-1 vaccine against TC-1 challenge) provided protection.

Conclusions:

• MHC class I expression status significantly impacts the efficacy of tumor vaccines.
• The lack of cross-protection between MHC class I+ and MHC class I- tumors, even with shared antigens, may necessitate tailored vaccine designs.
• Findings suggest potential limitations for polyvalent tumor vaccines targeting diverse MHC expression profiles in cancer immunotherapy.